Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass
Background COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2024-11-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/10/6/00154-2024.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841537070605008896 |
|---|---|
| author | Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson E. Robles-Hernández Bartolome R. Celli Raúl H. Sansores Maricruz Cassou-Martínez José L. Pérez Lara-Albisua Claudia González-González María E. Mayar-Maya Aloisa P. Hernández-Morales Rafael J. Hernández-Zenteno Ramcés Falfán-Valencia Ireri Thirión-Romero Oliver Pérez-Bautista Rogelio Pérez-Padilla |
| author_facet | Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson E. Robles-Hernández Bartolome R. Celli Raúl H. Sansores Maricruz Cassou-Martínez José L. Pérez Lara-Albisua Claudia González-González María E. Mayar-Maya Aloisa P. Hernández-Morales Rafael J. Hernández-Zenteno Ramcés Falfán-Valencia Ireri Thirión-Romero Oliver Pérez-Bautista Rogelio Pérez-Padilla |
| author_sort | Alejandra Ramírez-Venegas |
| collection | DOAJ |
| description | Background
COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV1) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City.
Methods
A pilot, single-centre, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V and 34 COPD-C patients received UMEC/VI.
Results
There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B (0.07 (95% CI 0.03–0.13), 0.06 (95% CI 0.03–0.12)) or COPD-C group (0.06 (95% CI 0.04–0.11), 0.08 (95% CI 0.05–0.13)), nor in the time of first exacerbation, nor FEV1 and IC. All groups showed improvement in dyspnoea and HRQL, independently of medication used.
Conclusions
Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnoea and HRQL. |
| format | Article |
| id | doaj-art-1bfc000511044465b88be32413961124 |
| institution | Kabale University |
| issn | 2312-0541 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj-art-1bfc000511044465b88be324139611242025-01-14T09:50:21ZengEuropean Respiratory SocietyERJ Open Research2312-05412024-11-0110610.1183/23120541.00154-202400154-2024Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomassAlejandra Ramírez-Venegas0Francisco Montiel-Lopez1Robinson E. Robles-Hernández2Bartolome R. Celli3Raúl H. Sansores4Maricruz Cassou-Martínez5José L. Pérez Lara-Albisua6Claudia González-González7María E. Mayar-Maya8Aloisa P. Hernández-Morales9Rafael J. Hernández-Zenteno10Ramcés Falfán-Valencia11Ireri Thirión-Romero12Oliver Pérez-Bautista13Rogelio Pérez-Padilla14 Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Respiratory Medicine, Medica Sur Clinic and Foundation, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Economy Faculty, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Imaging and Radiology Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Research Department of COPD and Tobacco Smoking, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico Background COPD due to biomass exposure (COPD-B) is highly prevalent in low- and middle-income countries, and there are no clinical trials designed to evaluate the effectiveness of the treatments currently recommended for patients with COPD due to cigarette smoking (COPD-C). The purpose of the study was to compare the efficacy of fluticasone furoate/vilanterol (FF/V) 100/25 μg and umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg on the rate of exacerbations, the time to first exacerbation, on dyspnoea, health-related quality of life (HRQL), forced expiratory volume in 1 s (FEV1) and inspiratory capacity (IC) during a period of 6 months in patients with COPD-B and COPD-C, at a third level referral centre in Mexico City. Methods A pilot, single-centre, open-label, parallel-group study included 132 patients with a history of at least two exacerbations. They were randomised to receive one of four treatment groups: 33 COPD-B patients received FF/VI 100/25 μg, 31 COPD-B patients received UMEC/VI 62.5/25 μg, 34 COPD-C patients received FF/V and 34 COPD-C patients received UMEC/VI. Results There were no differences in exacerbation rates between patients receiving FF/VI or UMEC/VI in either the COPD-B (0.07 (95% CI 0.03–0.13), 0.06 (95% CI 0.03–0.12)) or COPD-C group (0.06 (95% CI 0.04–0.11), 0.08 (95% CI 0.05–0.13)), nor in the time of first exacerbation, nor FEV1 and IC. All groups showed improvement in dyspnoea and HRQL, independently of medication used. Conclusions Among patients with COPD-B and COPD-C with a history of exacerbation, FF/VI was equally effective as UMEC/VI in preventing exacerbations and improving dyspnoea and HRQL.http://openres.ersjournals.com/content/10/6/00154-2024.full |
| spellingShingle | Alejandra Ramírez-Venegas Francisco Montiel-Lopez Robinson E. Robles-Hernández Bartolome R. Celli Raúl H. Sansores Maricruz Cassou-Martínez José L. Pérez Lara-Albisua Claudia González-González María E. Mayar-Maya Aloisa P. Hernández-Morales Rafael J. Hernández-Zenteno Ramcés Falfán-Valencia Ireri Thirión-Romero Oliver Pérez-Bautista Rogelio Pérez-Padilla Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass ERJ Open Research |
| title | Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass |
| title_full | Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass |
| title_fullStr | Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass |
| title_full_unstemmed | Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass |
| title_short | Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass |
| title_sort | effectiveness of ics laba and lama laba in copd due to biomass |
| url | http://openres.ersjournals.com/content/10/6/00154-2024.full |
| work_keys_str_mv | AT alejandraramirezvenegas effectivenessoficslabaandlamalabaincopdduetobiomass AT franciscomontiellopez effectivenessoficslabaandlamalabaincopdduetobiomass AT robinsonerobleshernandez effectivenessoficslabaandlamalabaincopdduetobiomass AT bartolomercelli effectivenessoficslabaandlamalabaincopdduetobiomass AT raulhsansores effectivenessoficslabaandlamalabaincopdduetobiomass AT maricruzcassoumartinez effectivenessoficslabaandlamalabaincopdduetobiomass AT joselperezlaraalbisua effectivenessoficslabaandlamalabaincopdduetobiomass AT claudiagonzalezgonzalez effectivenessoficslabaandlamalabaincopdduetobiomass AT mariaemayarmaya effectivenessoficslabaandlamalabaincopdduetobiomass AT aloisaphernandezmorales effectivenessoficslabaandlamalabaincopdduetobiomass AT rafaeljhernandezzenteno effectivenessoficslabaandlamalabaincopdduetobiomass AT ramcesfalfanvalencia effectivenessoficslabaandlamalabaincopdduetobiomass AT irerithirionromero effectivenessoficslabaandlamalabaincopdduetobiomass AT oliverperezbautista effectivenessoficslabaandlamalabaincopdduetobiomass AT rogelioperezpadilla effectivenessoficslabaandlamalabaincopdduetobiomass |